Skip to main content

Table 2 Estimated eligible population and study timeline by region in Stages I and II of the AVENIR trial

From: Age-based targeting of biannual azithromycin distribution for child survival in Niger: an adaptive cluster-randomized trial protocol (AVENIR)

Region Estimated eligible under-5 populationc Estimated eligible communitiesd Stage Ia Stage IIb
Year 1 Year 2 Year 3 Year 3 Year 4
Round 1 Round 2 Round 3e Round 4 Round 5 Round 6 Round 7 Round 8
Dosso 271,273 1800 X* X X X X* X X X
Tahoua (1st half) 245,944 1250    X X X X X X
Tahoua (2nd half) 245,944 1250     X X X X X
Maradi (1st half) 342,889 1700      X X X X
Maradi (2nd half) 342,890 1700       X X X
Zinder 452,241 3860        X X
Tillabéri 440,791 3070         X
Total 2,341,972 14,630         
  1. Round = one distribution of azithromycin and/or placebo; x = census and treatment; x* = census, resistance assessments, treatment
  2. a Stage I includes enrollment through the primary outcome analysis at 2.5 years from the first region enrollment
  3. b Stage II is dependent upon primary outcome results, available resources, and security restrictions
  4. c As estimated from projections by the Institute for Health Metrics and Evaluation multiplied by fraction of eligible grappes in each region
  5. d Communities with total populations between 250 and 2499 not designated as urban quartiers according to the 2012 Niger national census. Dosso region estimates further exclude communities known to be located within 5 km of district headquarters town
  6. Distance-based exclusions pending for the other 4 regions.
  7. e Interim analysis to be conducted at 18 months from the first enrollment